

E-ISSN: 2320-7078 P-ISSN: 2349-6800 JEZS 2020; 8(1): 267-269 © 2020 JEZS Received: 07-11-2019 Accepted: 09-12-2019

Dr. Rashmi Rajashekaraiah Department of Veterinary Pharmacology & Toxicology Veterinary College, Bengaluru, Karnataka, India

N Prakash

Department of Veterinary Pharmacology & Toxicology KVAFSU, Bidar, Karnataka, India

HD Narayanaswamy

Department of Veterinary Pathology, KVAFSU, Bidar, Karnataka, India

M Narayana Swamy

Department of Veterinary Physiology, KVAFSU, Bidar, Karnataka, India

D Rathnamma

Department of Veterinary Microbiology, KVAFSU, Bidar, Karnataka, India

PT Ramesh

Department of Veterinary Medicine, KVAFSU, Bidar, Karnataka, India

U Sunilchandra Department of Veterinary Pharmacology & Toxicology

Pharmacology & Toxicology KVAFSU, Bidar, Karnataka, India

CR Santhosh Department of Veterinary Pharmacology & Toxicology KVAFSU, Bidar, Karnataka, India

H Dhanalakshmi Department of Veterinary Parasitology, KVAFSU, Bidar, Karnataka, India

N Nagaraju Department of Veterinary Surgery and Radiology, KVAFSU, Bidar, Karnataka, India

Vanishree H Department Animal Husbandry and Veterinary Services Government of Karnataka, India

Corresponding Author:

Dr. Rashmi Rajashekaraiah Department of Veterinary Pharmacology & Toxicology Veterinary College, Bengaluru, Karnataka, India

Journal of Entomology and Zoology Studies

Available online at www.entomoljournal.com



Cytotoxicity screening of curcumin on HeLa cancer cell lines

Rashmi R, N Prakash, HD Narayanaswamy, M Narayana Swamy, D Rathnamma, PT Ramesh, U Sunilchandra, CR Santhosh, H Dhanalakshmi, N Nagaraju and Vanishree H

Abstract

Phytocompounds are most extensively studied as an alternative approach in cancer therapeutics. Curcumin is one of the leading compounds from turmeric that has been most extensively studied for its promising pharmacological effects. In the present study, the cytotoxicity potential of curcumin was determined by MTT [3-(4, 5-dimethylthiazolyl-2)-2, 5- diphenyltetrazolium bromide] assay on HeLa cancer cell lines. The MTT assay was conducted at 48h incubation to determine percent cell viability. The IC₅₀ values of curcumin was 3.36μ M. The curcumin showed dose-dependent cytotoxicity on cervical epithelioid adenocarcinoma cells. The *in vitro* cytotoxicity potential of curcumin in terms of percent cell viability proved to be more effective on HeLa cells.

Keywords: Curcumin, cytotoxicity, MTT, IC50, HeLa

1. Introduction

Cancer is a multistage disease characterized by uncontrolled and unregulated cellular growth ^[1, 2]. Recently, much attention has been focused on phytocompounds for combating major challenges in cancer therapy such as drug resistance, metastasis, and recurrence. The 74% of all drugs which are approved in cancer therapeutics from 1981 to 2002, were derived either from natural compounds or based on natural compounds ^[3]. Amongst various natural compounds, polyphenols are primarily involved in regulating cancer signaling pathways ^[4, 5, 6], inhibiting cancer cell proliferation resulting in tumor regression. Curcumin is a natural polyphenol obtained from the rhizome of *Curcuma longa* of the Zingiberaceae family ^[7, 8]. It has been used extensively from ancient time in the treatment of many diseases ^[9, 10]. It is widely available, non-toxic, and possesses different pharmacological activities such as antibacterial, antioxidant, antiviral, analgesic, anticancer, antifungal and anti-inflammatory ^[11, 12, 13, 14]. The anticancer effects of curcumin are important because it prevents the proliferation of cancer cells but does not harm healthy cells ^[15]. In the current study, an investigation was undertaken to determine the cytotoxicity of curcumin on HeLa cancer cell lines.

2. Materials and Methods

2.1 Materials

Curcumin (#C1386), Dimethly sulfoxide (#D8418) were purchased from Sigma-Aldrich Chemical Co. Ltd. Dulbecco's Modified Eagle's Medium (GE Healthcare Life Sciences, #SH30243.01), Dulbecco's phosphate-buffered saline (GE Healthcare Life Sciences, #SH30028.02). Trypan blue, absolute ethanol, MTT [3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide], trypsin, amphotericin, penicillin, streptomycin, fetal bovine serum, (Hi-Media Labs, Mumbai, India) and other reagents of analytical grade were also used in the study.

2.2 Cell lines and culture conditions

The HeLa cancer cell lines (National Centre for Cell Science, Pune, India) were used for *in vitro* cytotoxicity assay. The cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) (4.5g/L Glucose), supplemented with L-glutamine (4mM), penicillin 10,000 units/mL, 10% heat-inactivated fetal bovine serum (FBS), streptomycin 1000 μ g/mL and Amphotericin-B solution 25 μ g/ mL.

The cells were incubated at 37 $^{\circ}$ C in a humidified Atmosphere of 95 percent air and 5 percent CO₂. The adherent cells were detached using trypsin-EDTA solution 1X/0.25% after 24h of incubation. The Trypan blue dye exclusion method was followed for cell counting using the Luna automated cell counter (Logos Bio systems, USA).

2.3 Determination of cytotoxicity

The cytotoxicity of curcumin on HeLa cancer cell lines was determined by MTT (3-(4, 5-dimethylthiazolyl -2)-2, 5diphenyltetrazolium bromide) assay. The cell suspension of 200µL was seeded in 96-well micro plates at a density of 20,000 cells/well and incubated in 5% CO2 incubator at 37 °C for 24h, after which the cells were exposed to a graded concentration of 3.125, 6.25, 12.5, 25 and 50µM of curcumin and incubated for 48h. Later media was removed from all treated and vehicle control (1% DMSO) cells and replaced with fresh media containing MTT (0.5 mg/ml) and were reincubated for 3h at 37 °C. The MTT solution was removed and then the 100µL of DMSO was added to dissolve insoluble formazan crystals formed within the mitochondria of viable cells. The plate was incubated with DMSO for 5min with gentle shaking. The cell viability was determined by measuring the absorbance on a micro plate reader (ELx800, Bio Tek, USA) at λ max 570 nm. A dose-response curve was constructed and the concentration of curcumin that resulted in 50 percent inhibition of cell growth was calculated as the halfmaximal inhibitory concentration (IC₅₀). The IC₅₀ value was determined by a linear curve fit generated after obtaining dose-response to five different concentrations of curcumin. The cell viability percentages (y-axis) were plotted against increasing concentrations of curcumin on the x-axis. The IC₅₀ values were estimated by using the linear regression equation

$$y = mx + c$$

Where 50 is substituted for y, yielding x as the IC_{50} value.

Cell Viability (%) = $\frac{\text{Number of cells treated with the test item}}{\text{Number of untreated cells}} X 100$

2.4 Statistical analysis

The MTT assay data was subjected to linear regression analysis to obtain dose-response curves and IC_{50} values. The student t-test was carried out and all the values were expressed as Mean \pm SD (Graph Pad Prism, Version 5).

3. Results and Discussion

3.1 In vitro cytotoxicity assay

The IC₅₀ value of curcumin on HeLa cells was 3.36 μ M, (Fig.1b). The proliferation of HeLA cells was significantly (*p*<0.0001) inhibited by curcumin in a dose-dependent manner at 48h incubation (Fig.2). The treated HeLa cells with curcumin showed shrinkage and partial detachment, thus suggesting cytotoxicity of curcumin at 48h incubation (Fig.1b). The findings of our study indicated that curcumin in terms of percent cell viability on HeLa cell lines showed dose-dependent cytotoxicity ^[16, 17]. In conclusion, the successful results of the present study along with the additional set of investigations could make way the possibility of a combination of the curcumin as an adjuvant with the available conventional drugs to encounter drug resistance and adverse effects in cervical cancer.




Fig 1: Representative Images of cytotoxic effect of a) vehicle control b) curcumin on HeLa cell lines at 48h incubation (10X)




Fig 2: Histogram depiction of dose dependent cytotoxicity data of curcumin as determined by MTT assay on HeLa cell lines. Values are Mean \pm SD, n=3, (***p<0.0001)

4. Acknowledgement

The authors are grateful to SCSP/TSP grants, Government of Karnataka, India for funding the research work.

5. References

- Wang J, Qi L, Zheng S, Wu T. Curcumin induces apoptosis through the mitochondria-mediated apoptotic pathway in HT-29 cells. Journal of Zhenjiang University Science B. 2009; 10(2):93-102.
- Perez-Soto E, Estanislao-Gomez CC, Perez-Ishiwara DG, Ramirez-Celis C, Gomez-Garcia MC. Cytotoxic Effect and Mechanisms from Some Plant-Derived Compounds in Breast Cancer, 2019. DOI: 10.5772/intechopen.87177.
- 3. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. Journal

of Natural Products. 2003; 66(7):1022-1037.

- 4. Jakobek L. Interactions of polyphenols with carbohydrates, lipids and proteins. Food Chemistry. 2015; 175:556-567.
- 5. Ramos S. Cancer chemoprevention and chemotherapy: dietary polyphenols and signaling pathways. Molecular Nutrition and Food Research. 2008; 52:507-526.
- 6. Arora I, Sharma M, Tollefsbol TO. Combinatorial Epigenetics Impact of Polyphenols and Phytochemicals in Cancer Prevention and Therapy. International Journal of Molecular Sciences. 2019; 20:4567.
- Zamrus SNH, Akhtar MN, Yeap SK, Quah CK, Loh W, Alitheen NB *et al.* Design, synthesis and cytotoxic effects of curcuminoids on HeLa, K562, MCF-7 and MDA-MB-231 cancer cell lines. Chemistry Central Journal. 2018; 12:31.
- 8. Alibeiki F, Jafari N, Karimi M, Peeri Dogaheh H. Potent anti-cancer effects of less polar Curcumin analogues on gastric adenocarcinoma and esophageal squamous cell carcinoma cells. Scientific Reports. 2017; 7:2559.
- 9. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. European Journal of Cancer. 2005; 41(13):1955-1968.
- 10. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Molecular Cancer. 2011; 10:12.
- 11. Zaminpira S, Niknamian S. Anti-carcinogenic and therapeutic properties of curcumin. Journal of Cancer Research Metastasis. 2018; 1(2):23-34.
- Tomeh MA, Hadianamrei R, Zhao X. Review of Curcumin and Its Derivatives as Anticancer Agents. International Journal of Molecular Sciences. 2019; 20:1033.
- 13. Nagahama K, Utsumi T, Kumano T, Maekawa S, Oyama N, Kawakami J *et al.* Discovery of a new function of curcumin which enhances its anticancer therapeutic potency. Scientific Reports. 2016; 6:30962.
- Yuefeng D, Long Q, Zhang L, Shi Y, Liu X, Li X *et al.* "Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling. International Journal of Oncology. 2015; 47(6):2064-2072.
- 15. Anand P, Sundaram C, Jhurani S. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Letters. 2008; 267(1):133-64.
- Zhoa J, Zhoa Y, Zhang Y, Chen W. Anti-tumor effect of curcumin on human cervical carcinoma HeLa cells *in vitro* and *in vivo*. Chinese Journal of Cancer Research. 2007; 19:32.
- Ahmadi F, Ghasemi-Kasman M, Ghasemi S, Tabari MG, Pourbagher R, Kazemi S *et al.* Induction of apoptosis in HeLa cancer cells by an ultrasonic-mediated synthesis of curcumin-loaded chitosan-alginate-STPP nanoparticles. International Journal of Nano medicine. 2017; 12:8545-8556.